期刊文献+

原发性肺动脉高压的药物治疗进展 被引量:5

Progress in Treatment of Primary Pulmonary Hypertension
下载PDF
导出
摘要 原发性肺动脉高压是一种原因不明 ,预后不良的疾病 ,自从前列环素及内皮素受体拮抗剂等血管扩张剂临床应用以来 。
出处 《心血管病学进展》 CAS 2004年第2期153-155,共3页 Advances in Cardiovascular Diseases
  • 相关文献

参考文献19

  • 1[1]Rich S,Kaufman E,Levy P.The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension[J].N Engl J Med,1992,327(1):76. 被引量:1
  • 2[2]Barst RJ,Rubin LJ,Long wA,et al.A comparison of continuous intravenous eporprostenol(prostacyclin)with conventional therapy for primary pulmonary hypertension[J].N Engl J Med,1996,334(5):296-302. 被引量:1
  • 3[3]McLaughlin V,Genthner D,Panella M,et al.Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin)therapy in primary pulmonary hypertension[J].N Engl J Med,1998,338(5):273-277. 被引量:1
  • 4[4]Shapiro SM,Oudiz RJ,Cao T,et al.Primary pulmonary hypertension:improved long-term effects and survival with continuous intravenous epoprostenol infusion[J].J Am Coll Cardiol,1997,30(2):343-349. 被引量:1
  • 5[5]Badesch D,Tapson V,McGoon M,et al.Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease[J].Ann Intern Med,2000,132(6):425-434. 被引量:1
  • 6[6]Sebbag I,Rudski LG,Therrien J,et al.Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension[J].Am J Cardiol,2001,88(9):1060-1063. 被引量:1
  • 7[7]Simonneau G,Barst RJ,Galie N,et al.Continuous subcutaneous infusion oftreprostinil,a prostacyclin analogue,in patients with pulmonary arterial hyperten-sion:a double-blind,randomized,placebo-controlled trial[J].Am J Respir CritCare Med,2002,165(6):800-804. 被引量:1
  • 8[8]Nagaya N,Uematsu M,Okano Y.Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension[J].J Am Coll Cardiol,1999,34(4):1188-1192. 被引量:1
  • 9[9]Galie N,Humbert M,Vachiery JL,et al.Effects of beraprost sodium,an oralprostacyclin analogue,in patients with pulmonary arterial hypertension:a ran-domized,double-blind,placebo-controlled trial[J].J Am Coll Cardiol,2002,39`(9):1496-1502. 被引量:1
  • 10[10]Nagaya N,Shimizu Y,Satoh T,et al.Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension[J].Heart,2002,87(4):340-345. 被引量:1

同被引文献67

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部